Data as of Dec 26
| -0.004 / -0.57%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 3.25, with a high estimate of 3.50 and a low estimate of 3.00. The median estimate represents a +363.62% increase from the last price of 0.70.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.